Inhibition of allergen‐mediated mast cell activation by rosemary extract ( <i>Rosmarinus officinalis</i> L.)
Notice bibliographique
Résumé
The prevalence of allergic inflammatory disorders is increasing at an alarming rate, with 40–50% of school‐aged children suffering today and more than 25% of people living in a developed nation presently diagnosed or expected to develop, an allergic disease in their lifetime. This trend places a large economic burden on healthcare systems with $20B spent on treating these disorders in the USA in 2007. Mast cells are immune sentinels and a driving force in both normal and pathological contexts of inflammation. Allergen detection by the immune system results in production of allergen‐specific immunoglobulin E (IgE) antibodies. These antibodies bind to their high‐affinity receptor FcɛRI, which is constitutively expressed on the surface of mast cells. Crosslinking of FcɛRI by allergen‐bound IgE antibodies leads to mast cell degranulation (e.g. histamine) resulting in an early phase response, and the release of newly synthesized pro‐inflammatory mediators, contributing to a late phase response. The mitogen‐activated protein kinase (MAPK) family and, nuclear factor‐κ‐light‐chain‐enhancer of activated B cells (NF‐κB) pathways have been established to be driving mechanisms behind mast cell‐induced inflammation. Rosemary extract (RE) is rich in polyphenols, including rosmarinic acid (RA), carnosic acid (CA), and carnosol (CO), which have been shown to inhibit the MAPK and NF‐κB pathways in other cellular contexts in vitro and in in vivo animal models. However, the effect of these polyphenols on mast cell activation and degranulation has not been explored . Therefore, the aim of this study was to evaluate the potential of RE in modulating mast cell activation and FcɛRI signaling via these pathways toward understanding the mechanism of action and functional outcomes. Mast cells were sensitized with anti‐TNP IgE and were stimulated with the cognate allergen (TNP‐BSA) under stem cell factor (SCF) potentiation, and treated with 0 – 25 μg/mL RE. Samples were then collected for β‐hexosaminidase assay, quantitative polymerase chain reaction (qPCR), enzyme‐linked immunosorbent assay (ELISA) and, western blotting analysis. The β‐hexosaminidase assay demonstrated that RE treatment inhibited mast cell degranulation dose‐dependently to a maximum (down to 15% of control) at 25 μg/mL (p<0.001) RE. qPCR analysis showed that RE treatment at 25 μg/mL resulted in decreased gene expression of IL6 at both 60 and 120 mins (p<0.05), IL13 at 120 mins (p<0.05), TNF at 120 mins (p<0.05), CCL1 at both 60 (p<0.01) and 120 mins (p<0.05), CCL3 at both 60 and 120 minutes (p<0.05), and Rcan1 at 120 mins (p<0.05). ELISA analysis further supported the qPCR data showing decreases in pro‐inflammatory IL‐6 at 12 hrs (p<0.05) and TNF at 24 hrs (p<0.05). Western blot analysis demonstrated that RE treatment at both 5 and 25 μg/mL inhibited phosphorylation of p38‐MAPK at 5 mins. This work enhances our current understanding of mast cell functional modulation, mast cell signaling, and mechanistic activities of RE with relevance to innate defences and allergy. Support or Funding Information Supported by the Natural Sciences and Engineering Research Council of Canada (NSERC); Canada Foundation for Innovation (CFI); Government of Ontario; and Brock University. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,001 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,001 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».